CAPR Capricor Therapeutics Inc
Price (delayed)
$5.2
Market cap
$169.2M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.89
Enterprise value
$160.35M
Capricor Therapeutics, Inc., is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class cell and exosome-based therapeutics for the treatment and prevention of diseases. Capricor's lead
Highlights
Capricor Therapeutics's gross profit has surged by 187% YoY
CAPR's revenue has surged by 187% year-on-year
The EPS rose by 24% year-on-year but it has declined by 7% since the previous quarter
CAPR's quick ratio is up by 22% YoY but it is down by 13% QoQ
CAPR's equity is down by 38% since the previous quarter
Key stats
What are the main financial stats of CAPR
Market
Valuations
Earnings
Shares outstanding
32.54M
Market cap
$169.2M
Enterprise value
$160.35M
Price to earnings (P/E)
N/A
Price to book (P/B)
14.38
Price to sales (P/S)
6.1
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.91
Revenue
$27.15M
EBIT
-$27.95M
EBITDA
-$26.67M
Free cash flow
-$36.05M
Per share
Balance sheet
Liquidity
EPS
-$0.89
Free cash flow per share
-$1.13
Book value per share
$0.36
Revenue per share
$0.85
TBVPS
$1.2
Total assets
$38.28M
Total liabilities
$26.78M
Debt
$1.84M
Equity
$11.5M
Working capital
$8.31M
Debt to equity
0.16
Current ratio
1.37
Quick ratio
1.33
Net debt/EBITDA
0.33
Margins
Efficiency
Dividend
EBITDA margin
-98.2%
Gross margin
100%
Net margin
-102.9%
Operating margin
-110.5%
Return on assets
-60.9%
Return on equity
-220.3%
Return on invested capital
-289.6%
Return on capital employed
-175.5%
Return on sales
-102.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CAPR stock price
How has the Capricor Therapeutics stock price performed over time
Intraday
2.36%
1 week
24.4%
1 month
31.31%
1 year
-16.13%
YTD
6.34%
QTD
9.01%
Financial performance
How have Capricor Therapeutics's revenue and profit performed over time
Revenue
$27.15M
Gross profit
$27.15M
Operating income
-$30M
Net income
-$27.95M
Gross margin
100%
Net margin
-102.9%
Capricor Therapeutics's gross profit has surged by 187% YoY
CAPR's revenue has surged by 187% year-on-year
The net margin has surged by 67% year-on-year but it has declined by 15% since the previous quarter
The company's operating margin has surged by 66% YoY but it fell by 15% QoQ
Growth
What is Capricor Therapeutics's growth rate over time
Valuation
What is Capricor Therapeutics stock price valuation
P/E
N/A
P/B
14.38
P/S
6.1
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.91
The EPS rose by 24% year-on-year but it has declined by 7% since the previous quarter
CAPR's P/B is 87% higher than its 5-year quarterly average of 7.5
CAPR's equity is down by 38% since the previous quarter
CAPR's revenue has surged by 187% year-on-year
The price to sales (P/S) is 96% less than the 5-year quarterly average of 142.3 and 3.9% less than the last 4 quarters average of 6.2
Efficiency
How efficient is Capricor Therapeutics business performance
The ROS has soared by 67% year-on-year but it has declined by 15% since the previous quarter
CAPR's ROIC is down by 40% YoY and by 3.5% from the previous quarter
The ROE has increased by 32% YoY and by 4.9% QoQ
The ROA has decreased by 20% QoQ and by 6% YoY
Dividends
What is CAPR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CAPR.
Financial health
How did Capricor Therapeutics financials performed over time
Capricor Therapeutics's total assets is 43% higher than its total liabilities
The company's total liabilities fell by 38% YoY and by 14% QoQ
The current ratio has increased by 23% year-on-year but it has declined by 13% since the previous quarter
The debt is 84% smaller than the equity
The debt to equity has plunged by 80% YoY but it has grown by 45% from the previous quarter
CAPR's equity is down by 38% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.